Please email us at Sales@AmericanPharmaWholesale.com with our item No, NDC#,UPC#or best is product link. We are located in Oceanside, California. Search over 100,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name.
Menu

Rx Item-Ciprofloxacin 0.3% Drops 5ml By Leading Pharma

Ciprofloxacin 0.3% Drops 5ml By Leading Pharma Item No.: Rx3706835/M 3706835  UPC No.:361314656056 NDC No. 69315-0308-05   69315030805   69315-308-05   6931530805    UPC/GTIN No. 369315308059 3-69315-BRAND: CIPROFLOXACIN NDC: 61314-0656-05,61314065605 UPC: 3-61314-65605-6,361314656056 Sandoz/Falcon Pharma LtdOnly Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scopWant to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.Ciprofloxacin 0.3% Drops 5ml By Leading Pharma Item No.: Rx3706835/M 3706835  UPC No.:361314656056 NDC No. 69315-0308-05   69315030805   69315-308-05   6931530805    UPC/GTIN No. 369315308059 3-69315-

Rx Item-Ciprofloxacin 0.3% Drops 5ml By Leading Pharma

$16.80$15.69

Item No.: Rx3706835/M 3706835 UPC No.:361314656056 NDC No. 69315-0308-05 69315030805 69315-308-05 6931530805 UPC/GTIN No. 369315308059 3-69315-30805-9 369315-308059 MPN No. 8059 Only Lic.-Physician, Pharmacy, Dentist, Drug Mfg, Dist., Gov, Hospital, Lic.Lab, Naturalist, Naturopath, NP, Optometrist, Pharmacist, PA, Physical Therapist, Podiatrist, Research Co., Uni., VA, Vet & Wholesalers In Scope Of their Practice Can Order Rx Item. Rx Item No. Rx019719 Ciprofloxacin 0.3% Drops 5ml B

Have a question?

CIPROFLOXACIN - ciprofloxacin
Lupin Pharmaceuticals, Inc.

WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS

� Fluoroquinolones, including ciprofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see WARNINGS AND PRECAUTIONS (5.1)] including:



� Tendinitis and tendon rupture [see WARNINGS AND PRECAUTIONS (5.2)]

� Peripheral neuropathy [see WARNINGS AND PRECAUTIONS (5.3)]

� Central nervous system effects [see WARNINGS AND PRECAUTIONS(5.4)]

� Discontinue ciprofloxacin immediately and avoid the use of fluoroquinolones, including ciprofloxacin, in patients who experience any of these serious adverse reactions [see WARNINGS AND PRECAUTIONS (5.1)]. Fluroroquinolones, including ciprofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid ciprofloxacin in patients with known history of myasthenia gravis [see WARNINGS AND PRECAUTIONS (5.5)]

� Because fluoroquinolones, including ciprofloxacin, have been associated with serious adverse reactions [see WARNINGS AND PRECAUTIONS (5.1 to 5.15)], reserve ciprofloxacin for use in patients who have no alternative treatment options for the following indications:

� Acute exacerbation of chronic bronchitis [see INDICATIONS AND USAGE (1.10)]

� Acute uncomplicated cystitis [see INDICATIONS AND USAGE (1.11)]

� Acute sinusitis [see INDICATIONS AND USAGE (1.12)]

1 INDICATIONS AND USAGE

1.1 Skin and Skin Structure Infections
Ciprofloxacin for oral suspension is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes.

1.2 Bone and Joint Infections
Ciprofloxacin for oral suspension is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa.

1.3 Complicated Intra-Abdominal Infections
Ciprofloxacin for oral suspension is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis.

1.4 Infectious Diarrhea
Ciprofloxacin for oral suspension is indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni, Shigella boydii � , Shigella dysenteriae, Shigella flexneri or Shigella sonnei � when antibacterial therapy is indicated.

� Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients.

1.5 Typhoid Fever (Enteric Fever)
Ciprofloxacin for oral suspension is indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi. The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated.

1.6 Uncomplicated Cervical and Urethral Gonorrhea
Ciprofloxacin for oral suspension is indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae [see WARNINGS AND PRECAUTIONS (5.16)].

1.7 Inhalational Anthrax (Post-Exposure)
Ciprofloxacin for oral suspension is indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.

Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001 [see CLINICAL STUDIES (14.2)].

1.8 Plague
Ciprofloxacin for oral suspension is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of ciprofloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see CLINICAL STUDIES (14.3)].

1.9 Chronic Bacterial Prostatitis
Ciprofloxacin for oral suspension is indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis.

1.10 Lower Respiratory Tract Infections
Ciprofloxacin for oral suspension is indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae.

Ciprofloxacin for oral suspension is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae

Ciprofloxacin for oral suspension is indicated for the treatment of acute exacerbations of chronic bronchitis (AECB) caused by Moraxella catarrhalis.

Because fluoroquinolones, including Ciprofloxacin for oral suspension, have been associated with serious adverse reactions [see WARNINGS AND PRECAUTIONS (5.1 to 5.15)] and for some patients AECB is self-limiting, reserve Ciprofloxacin for oral suspension for treatment of AECB in patients who have no alternative treatment options.

1.11 Urinary Tract Infections
Urinary Tract Infections in Adults

Ciprofloxacin for oral suspension is indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli , Klebsiella pneumoniae , Enterobacter cloacae , Serratia marcescens , Proteus mirabilis , Providencia rettgeri , Morganella morganii , Citrobacter koseri , Citrobacter freundii , Pseudomonas aeruginosa , methicillin-susceptible Staphylococcus epidermidis , Staphylococcus saprophyticus , or Enterococcus faecalis.

Acute Uncomplicated Cystitis

Ciprofloxacin for oral suspension is indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus.

Because fluoroquinolones, including ciprofloxacin for oral suspension, have been associated with serious adverse reactions [see WARNINGS AND PRECAUTIONS (5.1 to 5.15)] and for some patients acute uncomplicated cystitis is self-limiting, reserve ciprofloxacin for oral suspension for treatment of acute uncomplicated cystitis in patients who have no alternative treatment options.

Complicated Urinary Tract Infection and Pyelonephritis in Pediatric Patients

Ciprofloxacin for oral suspension is indicated in pediatric patients aged one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli [see USE IN SPECIFIC POPULATIONS (8.4)] .

Although effective in clinical trials, ciprofloxacin for oral suspension is not a drug of first choice in the pediatric population due to an increased incidence of adverse reactions compared to controls, including reactions related to joints and/or surrounding tissues. Ciprofloxacin for oral suspension, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals [see WARNINGS AND PRECAUTIONS (5.12), ADVERSE REACTIONS (6.1), USE IN SPECIFIC POPULATIONS (8.4) and NONCLINICAL TOXICOLOGY (13.2)].

1.12 Acute Sinusitis
Ciprofloxacin for oral suspension is indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis.

? Because fluoroquinolones, including ciprofloxacin for oral suspension, have been associated with serious adverse reactions [see WARNINGS AND PRECAUTIONS ( 5.1 to 5.15)] and for some patients acute sinusitis is self-limiting, reserve ciprofloxacin for oral suspension for treatment of acute sinusitis in patients who have no alternative treatment options.

1.13 Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin for oral suspension and other antibacterial drugs, ciprofloxacin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin for oral suspension may be initiated before results of these tests are known; once results become available appropriate therapy should be continued.

As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.

2 DOSAGE AND ADMINISTRATION

Ciprofloxacin for oral suspension should be administered orally as described in the appropriate Dosage Guidelines tables.

2.1 Dosage in Adults
The determination of dosage and duration for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative microorganism, the integrity of the patient's host-defense mechanisms, and the status of renal and hepatic function.

Ciprofloxacin 0.3% Drops 5ml By Leading Pharma Item No.: Rx3706835/M 3706835  UPC No.:361314656056 NDC No. 69315-0308-05   69315030805   69315-308-05   6931530805    UPC/GTIN No. 369315308059 3-69315-
Ciprofloxacin 0.3% Drops 5ml B
Ciprofloxacin 0.3% Drops 5ml By Leading Pharma Item No.: Rx3706835/M 3706835 UPC No.:361314656056 NDC No. 69315-0308-05 69315030805 69315-308-05 6931530805 UPC/GTIN No. 369315308059 3-69315-

BRAND: CIPROFLOXACIN NDC: 61314-0656-05,61314065605 UPC: 3-61314-65605-6,361314656056 Sandoz/Falcon Pharma Ltd
Ciprofloxacin 0.3% Drops 5Ml By Sandoz F
BRAND: CIPROFLOXACIN NDC: 61314-0656-05,61314065605 UPC: 3-61314-65605-6,361314656056 Sandoz/Falcon Pharma Ltd

Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop
CIPROFLOXACIN HCL OPHTHAL
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

Ciprofloxacin 0.3% Drops 5ml By Leading Pharma Item No.: Rx3706835/M 3706835  UPC No.:361314656056 NDC No. 69315-0308-05   69315030805   69315-308-05   6931530805    UPC/GTIN No. 369315308059 3-69315-
Ciprofloxacin 0.3% Drops 5ml B
Ciprofloxacin 0.3% Drops 5ml By Leading Pharma Item No.: Rx3706835/M 3706835 UPC No.:361314656056 NDC No. 69315-0308-05 69315030805 69315-308-05 6931530805 UPC/GTIN No. 369315308059 3-69315-